← Eichor
Study identifier: NCT05894018 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Brachytherapy (Iodine-125 Seeds) and Fluzoparib Combination Therapy for Advanced Unresectable Soft Tissue Sarcoma

Condition: Sarcoma,Soft Tissue · Brachytherapy · Poly(ADP-ribose) Polymerase Inhibitors  ·  Sponsor: Fujun Zhang

PhasePhase 2
Planned participants32
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

To evaluate the effectiveness and safety of radioactive particles in combination with the PARP inhibitor fluzoparib in the treatment of advanced inoperable soft tissue sarcoma.

This description comes directly from the study's public registry record.

Talk to the study team

Fujun Zhang, Ph.D,M.D  ·  +8613826222266  ·  zhangfj@sysucc.org.cn

Dengyao Liu, Ph.D  ·  +8618599037139  ·  liudy1@sysucc.org.cn

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-sen University Cancer CenterGuangzhou, Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05894018